Novartis Settles Patent Suit Over Organ Transplant Drug

Law360, New York (December 12, 2013, 6:11 PM EST) -- Novartis AG has reached a tentative settlement of its patent infringement suit over Accord Healthcare Inc. USA’s pursuit of government approval for a generic form of the drug Myfortic, which prevents patients from rejecting transplanted organs, according to a joint motion filed Thursday in D.C. federal court.

The Swiss pharmaceuticals giant and North Carolina-based Accord asked U.S. District Judge Emmet G. Sullivan to stay the case — in which Novartis accused Accord of infringing three patents for the brand drug — for 60 days to "permit...
To view the full article, register now.